A novel coronavirus (2019-nCoV) has been featured on every headline this past week as the WHO declares the outbreak a global public-health emergency. The 2019-nCoV causes illness ranging from the common cold to mores severe diseases such as Severe Acute Respiratory Syndrome (SARS), which can spread from person-to-person. The CDC believes that symptoms may appear in as few as 2 days or as long as 14 days after exposure. Common symptoms include a fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe respiratory issues, kidney failure and even death.
The 2019-nCoV was first identified in Wuhan, China on December 31, 2019. It quickly traveled around the world and the United States reported its first case on January 21, 2020. Since the break out (as of January 30th), over 7,800 people have been infected and 170 people have died, according to statistics. However, scientists believe that the real number is likely higher.
There is currently no vaccine to protect against the 2019-nCoV, nor any specific antiviral treatment. The best way to prevent the infection is to avoid being exposed to the virus. Government scientists in China, the United States and Australia, as well as those working at Johnson & Johnson, Moderna Therapeutics and Inovio Pharmaceuticals are all working quickly to develop a new vaccine. According to the New York Times, “The hunt began January 10th, when Chinese scientists posted the genetic make-up of the virus on a public database. The next morning, researchers at the National Institute of Health’s Vaccine Research Center in Maryland went to work. Within hours, they had pinpointed the parts of the genetic code that could be used to make a vaccine.”
Despite the quick response from several teams of scientist around the world, creating a vaccine for the 2019-nCoV can be a very long and expensive process. The first step is to identify the natural or synthetic antigens that might help prevent it. Then scientist will study how it interacts on a cellular level. After they are able to identify that it will be safe and effective for humans, clinical trials begin for Phases 1 – 3 research. After a successful Phase 3 trial (which could take up to several months or years), the manufacturer will submit for a license through the FDA, and it will be available for the general public. The only way to create a vaccine and determine if it is effective is to perform research studies at sites similar to Rochester Clinical Research, and provide the data to confirm that a vaccine is safe and effective. If you would like to help advance medicine and change lives and join a vaccine research study, please see below what we have available . Be sure to check back often, as we have new studies starting all the time.
Rochester Clinical Research is currently seeking volunteers who are 18 years or older, who have not had a flu shot in the last 6 months, for an mRNA multivalent influenza vaccine study. The study could last up to 6 months and includes up to 5 visits to our office. If you qualify, compensation is available for your time and travel.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Featured
Rochester Clinical Research is currently seeking volunteers who are 65 years and older for an Influenza vaccine study. The purpose of this study will be to evaluate the safety and immunogenicity of an mRNA vaccine to prevent influenza. Compensation for time and travel is available for around $630 to those who qualify.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is currently looking for volunteers between the ages of 18 to 59 years old to participate in an RSV study. This study is for people who are considered high-risk, due to underlying health conditions. The study will last approximately 7-8 months and could include 2-3 office visits. Compensation will be available for the trial-related time.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Featured
Rochester Clinical Research is currently seeking participants who are between the ages of 18-60 years old for an HSV-2 genital herpes vaccine study. This study is approximately 15 months long and includes 10 office visits and 12 telephone calls. To qualify for this study, you must have had a diagnosis of genital herpes for at least 1 year. Compensation for your trial-related time is available.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is currently seeking participants between the ages of 18 to 49 and 60 to 80 years old for a norovirus vaccine study. The study is approximately 14 months long and includes 11 office visits and 8 telephone calls. Compensation for this study is $125 per office visit and $25 per phone call completed.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Featured
Rochester Clinical Research is currently enrolling children between the ages of 2-17 years old for a pediatric RSV vaccine study. The study is approximately 6 months long and will include 2 visits to our office and 2 phone calls. Compensation of $125 per office visit and $60 per phone visit is available for trial-related time.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Featured
Rochester Clinical Research is seeking volunteers between the ages of 60-85 years old for an investigational RSV and human metapneumovirus vaccine study. The study could last approximately 12 months long and include 7 visits to our office along with 5 telephone calls. During this study, you will be compensated for your participation up to $200 per office visit and $50 per phone call.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is seeking participants between the ages of 18-70 years old for an adult Lyme Disease vaccine study. The study is approximately 19 months long and will include 12-14 visits to our office during that time. There is a 12.5% chance of a placebo in this study. Compensation for your trial-related time will be provided.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is currently seeking participants who are 50 years or older for a Pneumococcal vaccine research study. The length of the study is 6 months long and it includes approximately 3-4 visits to the office and 6 telephone calls. To qualify, you can’t have had a previous pneumococcal vaccine. For your participation, you will be compensated for your trial related time.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is currently seeking volunteers between the ages of 18-50 years old, who have not had a flu shot in the last 6 months, for an mRNA multivalent influenza vaccine study. The study could last up to 7 months and includes up to 6 visits to our office and 2 phone/virtual contacts. If you qualify, compensation is available for your time and travel.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is looking for participants 12 -17 years old for a Covid-19 booster study. This study is approximately 12 months long and includes 5 visits to our office along with 3 telephone calls. Compensation is available if you qualify to participate.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is currently seeking healthy volunteers between the ages of 18-55 years old to participate in an mRNA vaccine study to help potentially prevent the Epstein-Barr Virus. The study is 13 months long and includes 11 visits to our office. Compensation is available for your time and travels to participate.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is currently looking for individuals to join a vaccine study for the varicella-zoster virus. Varicella is a herpesvirus that can cause chickenpox and shingles infections. The purpose of this study is to evaluate the safety and effectiveness of an mRNA vaccine against the virus. RCR is seeking participants between the ages of 50-69 years old who have not previously received a shingles vaccine. This study could last between 8-12 months to 5 years long and includes at least 10-15 office visits. Reimbursement to participate is available for up to $128 per office visit and $5 for every diary entry completed.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is currently seeking volunteers between the ages of 9-15 years old to participate in a preventative CMV vaccine study. The purpose of this study is to vaccinate children against the virus to prevent them from spreading it to adults, especially women that may be planning on becoming pregnant in the foreseeable future. The study is approximately 18 months long and includes 12 visits in total.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Featured
There is currently no vaccine to prevent or protect against Lyme. RCR is currently conducting a vaccine study to help prevent Lyme disease from infecting adolescents between the ages of 5 to 17. This study will last approximately 24 months with 6 visits to our RCR office and 2 telephone calls.
View Trial Details *Compensation for time and travel may be available to those who qualify.
Rochester Clinical Research is currently seeking born-female volunteers who are 16 or 17 years old to participate in a CMV vaccine study. The purpose of this study is to find a safe and effective vaccine against Cytomegalovirus.
View Trial Details 
